HomeICPT • BMV
add
Intercept Pharmaceuticals Ord Shs
Previous close
$329.00
Year range
$329.00 - $329.00
Market cap
794.36M USD
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2023info | Y/Y change |
|---|---|---|
Revenue | 88.79M | 14.44% |
Operating expense | 86.95M | -0.41% |
Net income | -2.79M | -101.04% |
Net profit margin | -3.14 | -100.91% |
Earnings per share | 0.08 | -99.20% |
EBITDA | 1.74M | 117.27% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 322.71M | -34.25% |
Total assets | 393.16M | -29.72% |
Total liabilities | 321.32M | -28.87% |
Total equity | 71.84M | — |
Shares outstanding | 41.83M | — |
Price to book | 191.28 | — |
Return on assets | 0.93% | — |
Return on capital | 1.18% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2023info | Y/Y change |
|---|---|---|
Net income | -2.79M | -101.04% |
Cash from operations | 16.69M | 200.59% |
Cash from investing | 59.77M | -81.97% |
Cash from financing | -110.00M | 57.27% |
Net change in cash | -33.70M | -163.39% |
Free cash flow | 16.70M | 211.23% |
About
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Wikipedia
CEO
Founded
2002
Website
Employees
341
